© 1999 European Society of Cardiology
The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS)
* Corresponding author. Department of Cardiology University of Hull, Castle Hill Hospital, Kingston-upon-Hull, HU16 5JQ, UK
 |
Abstract |
|---|
Background: Carvedilol improves left ventricular (LV) function when heart failure is due to LV systolic dysfunction, but the magnitude of the response is heterogeneous among patients with coronary disease, possibly reflecting the presence or volume of hibernating myocardium. Aims: The primary objective of the study is to determine whether the presence of hibernating myocardium predicts the magnitude of improvement in LV ejection fraction in response to carvedilol among patients with heart failure and LV systolic dysfunction due to coronary disease.
Methods: The study is a prospective, randomised, parallel-group, double-blind, multi-centre study comparing carvedilol and placebo over a period of approximately 6 months in the above patient population. The primary end-point is the comparison of the mean change, from baseline to the final visit, in radionuclide-determined LV ejection fraction among patients on placebo with those on carvedilol stratified according to the presence of hibernating myocardium. Hibernating status will be determined by a combination of echocardiographic and myocardial perfusion (technetium-99m sestamibi) imaging.
Results: 255 patients have undergone screening tests of which 207 have been randomised so far. The study intends to randomise 400 patients and the first report of results is expected in 2000.
Conclusions: As far as we are aware this is the first randomised controlled trial to investigate the effects of treatment in patients stratified according to the presence of hibernating myocardium. The study will provide insights into the prevalence of myocardial hibernation, its natural history, and its influence on prognosis as well as the interaction between the presence of hibernating myocardium and the effects of treatment with carvedilol.
Key Words: Heart failure • Hibernating myocardium • Beta-blockers
Accepted April 7, 1999
A double-blind, randomised, multi-centre study of oral carvedilol versus placebo in patients with chronic stable heart failure due to left ventricular systolic dysfunction, with or without hibernating myocardium
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. I.W. Galasko and A. Lahiri The non-invasive assessment of hibernating myocardium in ischaemic cardiomyopathy--a myriad of techniques Eur J Heart Fail, June 1, 2003; 5(3): 217 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.G.F. Cleland, N. Freemantle, S.G. Ball, R.S. Bonser, P. Camici, S. Chattopadhyay, D. Dutka, J. Eastaugh, J. Hampton, S. Large, et al. The heart failure revascularisation trial (HEART): rationale, design and methodology Eur J Heart Fail, June 1, 2003; 5(3): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Palazzuoli, F. Bruni, L. Puccetti, M. Pastorelli, P. Angori, A.L. Pasqui, and A. Auteri Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure Eur J Heart Fail, December 1, 2002; 4(6): 765 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Coletta, S. Thackray, N. Nikitin, and J. G.F. Cleland Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL Eur J Heart Fail, June 1, 2002; 4(3): 381 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Thackray, A. Coletta, P. Jones, A. Dunn, A. L. Clark, and J. G.F. Cleland Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF Eur J Heart Fail, August 1, 2001; 3(4): 491 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D.R. Thackray, K. K.A. Witte, A. Khand, A. Dunn, A. L. Clark, and J. G.F. Cleland Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure Eur J Heart Fail, January 1, 2001; 3(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Witte, S. Thackray, A. L. Clark, M. Cooklin, and J. G.F. Cleland Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART Eur J Heart Fail, December 1, 2000; 2(4): 455 - 460. [Abstract] [Full Text] [PDF]
|
|